Next Science Ltd (ASX: NXS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Next Science Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $76.57 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 291.70 million
Earnings per share -0.070
Dividend per share N/A
Year To Date Return -22.06%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Next Science Ltd (ASX: NXS)
    Latest News

    Man pointing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why ANZ, Next Science, Macmahon, and Pointsbet shares are racing higher

    These ASX shares are having a good session on Thursday.

    Read more »

    Man pointing at a blue rising share price graph.
    Healthcare Shares

    Guess which ASX healthcare share is booming 28% on a sales boost

    Investors are bidding up the ASX healthcare share after the company reported it’s on track to substantially exceed product sales…

    Read more »

    Rising arrow on a blue graph symbolising a rising share price.
    Healthcare Shares

    Next Science shares defy ASX market slump to surge 8%

    Next Science shares are set to finish Thursday's trading session on a high note.

    Read more »

    A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
    Healthcare Shares

    Here's why the Next Science (ASX:NXS) share price is rocketing 11% today

    The company's shares are on fire this Monday.

    Read more »

    A man scratches his head in confusion.
    Healthcare Shares

    What happened to the Next Science (ASX:NXS) share price last earnings season?

    Shares in the Aussie biotech were smashed on Friday before recovering late in the day

    Read more »

    medical doctor performing surgery using surgical instruments
    Share Gainers

    Next Science (ASX:NXS) share price jumps on record revenue growth

    A surge in revenue during the first half of 2021 puts the Next Science share price in the green today...

    Read more »

    Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
    Technology Shares

    Next Science (ASX:NXS) share price swings on lowered earnings update

    The Next Science share price went into a spin after a lowered earnings guidance sent investors running.

    Read more »

    three excited doctors with hands in the air
    Healthcare Shares

    Here's why the Next Science (ASX:NXS) share price finished higher today

    The medical research company has finished the day strongly after one of its products was given TGA approval.

    Read more »

    investor looking up as if watching asx share price
    Healthcare Shares

    Next Science (ASX:NXS) share price falls despite 'exciting future ahead'

    The Next Science Ltd (ASX: NXS) share price slumped today following the company's 2021 AGM presentation. Let's take a closer look.

    Read more »

    A boy looks up and points his fingers to the sky in celebration pose.
    Share Gainers

    Why Doctor Care Anywhere, Next Science, NIB, & Talga are charging higher

    Next Science Ltd (ASX:NXS) and NIB Holdings Limited (ASX:NHF) are two of four ASX shares that are charging notably higher…

    Read more »

    Rising healthcare ASX share price represented by doctor giving thumbs up
    Healthcare Shares

    Why the Next Science (ASX:NXS) share price opened 40% higher

    The Next Science Ltd (ASX: NXS) share price is shooting for the moon after the company's latest announcement. Click on…

    Read more »

    Two men react in shock at Evolution share price drop record profit
    Share Fallers

    Why Alumina, Delorean, Next Science, & Pushpay shares are tumbling lower

    Next Science Ltd (ASX:NXS) and Pushpay Holdings Ltd (ASX:PPH) shares are two of four tumbling lower on Tuesday. Here's why...

    Read more »

    NXS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Next Science Ltd

    Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.

    NXS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Jun 2024 $0.26 $0.00 0.00% 114,454 $0.27 $0.27 $0.26
    12 Jun 2024 $0.27 $0.00 0.00% 92,344 $0.26 $0.27 $0.25
    11 Jun 2024 $0.27 $0.00 0.00% 37,285 $0.25 $0.27 $0.25
    07 Jun 2024 $0.27 $0.00 0.00% 21,344 $0.27 $0.27 $0.27
    06 Jun 2024 $0.27 $-0.01 -3.64% 110,220 $0.25 $0.27 $0.25
    05 Jun 2024 $0.28 $0.00 0.00% 57,051 $0.28 $0.28 $0.26
    04 Jun 2024 $0.28 $0.01 3.77% 226,512 $0.27 $0.30 $0.27
    03 Jun 2024 $0.27 $0.01 3.85% 37,951 $0.26 $0.27 $0.26
    31 May 2024 $0.26 $0.01 4.00% 63,536 $0.25 $0.26 $0.25
    30 May 2024 $0.25 $-0.01 -3.92% 18,918 $0.26 $0.26 $0.25
    29 May 2024 $0.26 $-0.01 -3.77% 151,381 $0.28 $0.28 $0.25
    28 May 2024 $0.27 $-0.01 -3.70% 85,802 $0.27 $0.27 $0.26
    27 May 2024 $0.27 $0.01 3.77% 75,977 $0.26 $0.28 $0.25
    24 May 2024 $0.27 $0.02 8.00% 202,746 $0.25 $0.27 $0.23
    23 May 2024 $0.25 $-0.01 -3.85% 172,041 $0.27 $0.28 $0.25
    22 May 2024 $0.26 $-0.03 -10.34% 281,876 $0.29 $0.30 $0.25
    21 May 2024 $0.29 $-0.02 -6.45% 328,572 $0.30 $0.30 $0.26
    20 May 2024 $0.31 $-0.01 -3.17% 145,104 $0.31 $0.32 $0.29
    17 May 2024 $0.32 $-0.02 -5.97% 332,319 $0.34 $0.35 $0.29
    16 May 2024 $0.34 $-0.04 -10.67% 27,378 $0.36 $0.36 $0.33
    15 May 2024 $0.38 $-0.01 -2.63% 97,170 $0.39 $0.39 $0.38
    14 May 2024 $0.38 $0.00 0.00% 118,281 $0.38 $0.38 $0.36

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Nov 2023 Grant Hummel Issued 309,524 $130,000
    Placement.
    01 Nov 2023 Aileen Stockburger Issued 524,801 $220,416
    Placement.
    01 Nov 2023 Harry Hall(IV) Issued 200,000 $54,440
    Placement.
    31 Jul 2023 Judith Mitchell Transfer 420,000 $220,500
    Off-market transfer. Assuming off-market transfer of shares
    31 Jul 2023 Judith Mitchell Transfer 420,000 $220,500
    Off-market transfer. Assuming off-market transfer of shares

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Grant Hummel Non-Executive Director Aug 2023
    Mr Hummel was part of Next Science's ASX listing deal team in 2019. He has been a partner of a major Australian law firm, for over fifteen years. Grant has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients.
    Ms Aileen Stockburger Non-Executive DirectorNon-Executive Chairman Oct 2018
    Mr Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Aileen led Johnson & Johnson's efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson's medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He held dirctorships in Microbot Medical Inc. as Non Executive Director from last 3 years. He is Member of Risk, People & Culture Committee.
    Ms Katherine (Kathy) Ostin Non-Executive Director Oct 2023
    Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in aged care and healthcare sectors, having established and led KPMG's New South Wales Health, Ageing and Human Services audit practice from 2006 to 2017. During her 24 years with KPMG, Kathy worked in Australia, the US, Asia, and the UK. She is Chair of Risk Committee.
    Mr Harry Thomas Hall(IV) Chief Executive OfficerManaging Director Jul 2023
    Mr Hall has more than 28 years' experience in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. Prior to joining Next Science, He was a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes, a subsidiary of Johnson and Johnson (NYSE:JNJ), and completed the launch of the first surgical robot developed by JNJ / DePuy Synthes. He joined DePuy Synthes in 1997 where he held senior roles including Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, He was responsible for a global portfolio and execution strategy for a US$3.2bn platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, He created and sustained personal relationships with well over one hundred key opinion leaders worldwide.
    Ms Gillian Maria Nairn Company Secretary Jun 2018
    -
    Gillian Maria Nairn Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 59,990,423 20.57%
    Auckland Trust Company Ltd <Second Pacific Master Superannuation Fund> 56,019,938 19.20%
    Ubs Nominees Pty Ltd 16,528,388 5.67%
    Hsbc Custody Nominees (Australia) Limited A/C 2 11,839,023 4.06%
    Mr Charles Robert Dirck Wittenoom 5,118,880 1.75%
    Judith Lee Mitchell 4,706,975 1.61%
    Dr Matthew Franco Myntti 4,171,824 1.43%
    Citicorp Nominees Pty Limited 3,815,931 1.31%
    Mr James Fong Seeto 3,000,000 1.03%
    Bnpp Noms Pty Ltd Hub24 Custodial Serv Ltd 2,925,007 1.00%
    J P Morgan Nominees Australia Pty Limited 2,921,688 1.00%
    S G Andrew Pty Ltd <S G Andrew Super Fund A/C> 2,745,000 0.94%
    Mr Dean Anthony Mackenzie 2,514,258 0.86%
    Bond Street Custodians Limited <Lam1 D08047 A/C> 2,460,427 0.84%
    Mr Evan Philip Clucas & Ms Leanne Jane Weston<Kuranga Nursery Super A/C> 2,251,187 0.77%
    Belgravia Strategic Equities Pty Ltd 1,965,000 0.67%
    Twenty Fifth Elporto Pty Ltd <Twenty Fifth Elporto Sf A/C> 1,800,000 0.62%
    Brook St Smsf Pty Ltd <Brook St Smsf A/C> 1,255,702 0.43%
    Retzos Executive Pty Ltd <Retzos Executive S/Fund A/C> 1,057,146 0.36%
    Mr Timothy Ian Douglas 1,032,075 0.35%

    Profile

    since

    Note